The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986 on ClinicalTrials.gov · last registry update 2017-03-08

An unusually large phase 3: 987 participants, more than double the 424 typical for the stage. The sponsor logged completion for April 2010. Primary outcome, as filed: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 987
Started: 2009-03
Primary completion: 2010-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.